Investors & Media

Sep 22, 2020 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Sep 22, 2020 / Sep 22, 2020 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

9/8/20

BELLUS Health Announces Design for its Phase 2b Trial with BLU-5937 in Refractory Chronic Cough
- D ouble-blind, 4-week placebo controlled, parallel arm trial will evaluate the efficacy and safety of 3 doses of BLU-5937 in 280 patients with refractory chronic cough – - Trial to recruit patients with baseline cough count ≥25 coughs per hour -- RELIEF Phase 2 trial results demonstrated...
Read More
9/3/20

BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
LAVAL, Quebec --(BUSINESS WIRE)--Sep. 3, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced...
Read More
8/13/20

BELLUS Health Reports Second Quarter 2020 Financial Results and Business Highlights
- Phase 2b Trial Design for BLU-5937 in Refractory Chronic Cough to be Announced in Q3 2020 - LAVAL, Quebec --(BUSINESS WIRE)--Aug. 13, 2020-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for...
Read More